Advertisement
Advertisement
U.S. markets open in 1 hour 35 minutes
Advertisement
Advertisement
Advertisement
Advertisement

bluebird bio, Inc. (BLUE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.77+0.32 (+5.87%)
At close: 04:00PM EDT
5.62 -0.15 (-2.60%)
Pre-Market: 07:34AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Inside Bar (Bullish)

Inside Bar (Bullish)

Previous Close5.45
Open5.47
Bid0.00 x 900
Ask5.75 x 1400
Day's Range5.43 - 5.82
52 Week Range2.87 - 17.85
Volume5,154,196
Avg. Volume8,204,285
Market Cap444.993M
Beta (5Y Monthly)1.16
PE Ratio (TTM)N/A
EPS (TTM)-10.43
Earnings DateNov 03, 2022 - Nov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.78
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for BLUE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • bluebird bio, Inc.
    Analyst Report: AMGEN Inc.Amgen, based in Thousand Oaks, California, is a leading global biotech company. Its key products include Repatha, Kyprolis, Prolia, Xgeva, Neulasta, and Enbrel. The shares are a component of the S&P 500.
    Rating
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • Motley Fool

    Is This Growth Stock Undervalued?

    Biotech company Bluebird Bio (NASDAQ: BLUE) is currently riding high. Despite these accomplishments, Bluebird is still a tiny company with a market cap of just $475 million. Of note, Skysona had previously earned marketing authorization in Europe, but Bluebird exited the European market last year for reasons that may also prove to be a challenge in the U.S. (more on that in a bit).

  • Motley Fool

    Do Back-to-Back Approvals Make This Biotech Stock a Buy Now?

    This drugmaker has earned two new drug approvals in as many months, but its success isn't reflected in its market valuation yet.

  • Zacks

    Bluebird (BLUE) Surges 15.7%: Is This an Indication of Further Gains?

    Bluebird (BLUE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Advertisement
Advertisement